A recent study to compare the consistency and accuracy of 3.0-T breast MRI interpretation between manual and fully automated kinetic analyses suggests that CAD has the potential to improve the discrimination of benign from malignant breast lesions at 3.0-T MRI1. Additionally, it shows that CAD may decrease the heterogeneity of interpretation across radiologists of varying levels of experience in breast MR interpretation.
MEDRAD is now piloting a CAD distribution partnership in Boston, Cleveland, Pittsburgh, Dallas, Denver, Sacramento, and Atlanta. The pilot extends MEDRAD’s existing Europe distribution agreement with Merge CAD, and furthers MEDRAD’s commitment to extending the breast MRI resources available for clinicians and patients. CADstream applications for liver and prostate MRI are also available.
CADstream, the Merge CAD product MEDRAD now distributes, improves quality, standardization and efficiency of study analysis, reporting and interventional planning.
1Carla Meeuwis, Department of Radiology, Alysis Zorggroep, Rijnstate Hospital, Wagnerlaan 55, 6815 AD Arnhem, The Netherlands.